1000025-92-2 Usage
General Description
3,5-bis-benzyloxy-pyridine-2-carbonitrile is a chemical compound with the molecular formula C21H15N3O2. It is a pyridine derivative with two benzyloxy substituents and a cyano group attached to the 2-carbon of the pyridine ring. 3,5-bis-benzyloxy-pyridine-2-carbonitrile is commonly used in organic synthesis and medicinal chemistry as a building block in the preparation of various pharmaceuticals and bioactive molecules. Its unique structure and properties make it a valuable intermediate for the synthesis of diverse compounds with potential biological activity. Additionally, its versatile reactivity and functional groups make it a valuable tool for the development of new chemical reactions and synthetic methodologies.
Check Digit Verification of cas no
The CAS Registry Mumber 1000025-92-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,0,2 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1000025-92:
(9*1)+(8*0)+(7*0)+(6*0)+(5*0)+(4*2)+(3*5)+(2*9)+(1*2)=52
52 % 10 = 2
So 1000025-92-2 is a valid CAS Registry Number.
1000025-92-2Relevant articles and documents
COMPOUNDS HAVING HEPATIAL DISEASE EFFECTIVE
-
Paragraph 0140-0141; 0147, (2021/01/29)
The invention discloses a compound with a hepatopathy curative effect, and the compound is a compound shown as a general formula (I), an optical isomer or pharmaceutically acceptable salt thereof, canbe applied to treatment or prevention of hepatopathy, particularly to drugs for treating or preventing fatty liver, liver fibrosis or liver cirrhosis, and has a good application prospect.
EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO
-
Paragraph 0548; 0549, (2017/08/01)
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
